Ibio SEC Filings

iBio, Inc. (IBIO) reported an insider equity grant to its Chief Legal Officer. On 10/20/2025, the officer received a stock option to purchase 55,000 shares of common stock at an exercise price of $0.893 per share.

The option vests with 25% on the one-year anniversary of the grant, then the remainder in equal quarterly installments over 36 months, contingent on continued employment. The option becomes exercisable beginning 10/20/2026 and expires on 10/19/2035. The filing lists ownership of these derivative securities as Direct.

iBio, Inc. (IBIO) reported an insider equity award. Martin Brenner was granted 180,000 stock options at an exercise price of $0.893 on 10/20/2025.

The options vest 25% on 10/20/2026, with the remainder vesting in equal quarterly installments over 36 months, and they expire on 10/19/2035. Following the grant, 180,000 derivative securities are beneficially owned directly. Brenner is the company’s Chief Executive Officer, Chief Scientific Officer, and a Director. The transaction was coded A (grant) on Form 4.

iBio, Inc. is asking shareholders to vote on four proposals at its 2025 Annual Meeting: election of directors; ratification of Grassi & Co., CPAs, P.C. as independent auditors for the fiscal year ending June 30, 2026; an advisory Say-on-Pay vote; and an advisory Say-on-Frequency vote. Proxy materials and the Form 10-K for the year ended June 30, 2025 will be mailed to stockholders and the shareholder list will be available for inspection before the meeting.

The filing discloses executive pay details for Chief Scientific Officer Dr. Martin Brenner: his prior base salary was $405,000, he received interim CEO stipend payments of $7,500 per month, and a grant-date RSU award valued at approximately $91,000. Under a restated employment agreement effective July 1, 2024, his base salary was set at $522,365 with a bonus target of 50% for fiscal year 2025. The proxy explains the company’s peer-group selection (preclinical to Phase I/II biotech, preference for AI-enabled companies, market cap $100M, headcount under 100) and discusses stock-based compensation accounting under ASC Topic 718.

iBio, Inc. reported continued development-stage operations with negative operating cash flow of approximately $15.3 million and an operating capital deficit of about $15.3 million as of June 30, 2025, versus an $18.6 million deficit a year earlier. The company had 19,349,201 shares outstanding at June 30, 2025, up from 8,623,676 a year earlier, reflecting multiple equity financings including a 2025 Private Placement that generated approximately $655,000 and warrant exercises and inducement sales that produced aggregate gross proceeds of about $6.2 million. Material transactions include the acquisition of RubrYc (AI drug-discovery assets and related candidates) and CDMO facility purchases financed in part by a secured term loan and settlement arrangements. The filing describes extensive regulatory, clinical, manufacturing and collaboration risks for its vaccine and antibody programs, significant reliance on third-party manufacturers and collaborators, and previously identified internal control weaknesses that were remediated.

iBio, Inc. filed a Form 8-K to report that it issued a press release announcing its financial results for the fiscal year ended June 30, 2025. The press release is furnished as Exhibit 99.1 to the report.

The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions and will not be incorporated by reference into other SEC filings. The report is signed on behalf of iBio by Chief Legal Counsel Marc A. Banjak.

Affinity Healthcare Fund, LP and its investment adviser Affinity Asset Advisors, LLC disclosed a passive stake in iBio, Inc. The filing reports the Fund holds economic and voting interests in warrants exercisable into 4,280,000 shares of iBio common stock, representing 9.99% of the class on a reported basis. The filing explains a beneficial ownership limitation that prevents full exercise of all warrants without exceeding 9.99%, meaning the maximum number of shares that may be issued upon exercise without breaching that limit is 2,391,070. Voting and dispositive power over the reported securities are shared between the Fund and the Advisor.

Point72 entities and Steven A. Cohen reported beneficial ownership of 14,289,118 shares of iBio, Inc. common stock, representing 9.9% of the outstanding class as of August 22, 2025. The reported position includes 14,280,000 shares issuable upon exercise of warrants, but those warrants are subject to a 9.99% exercise blocker so some warrants are not currently exercisable.

The filing states Point72 Asset Management, Point72 Capital Advisors and Mr. Cohen share voting and dispositive power over the reported shares through Point72 Associates and related arrangements. The cover pages and Item 4 disclose shared voting and dispositive power only; none of the reporting persons claim sole voting or dispositive power over the reported shares.

iBio, Inc. reported a material event filing that discloses a financing-related package of documents. The filing attaches an underwriting agreement with Leerink Partners as representative of the underwriters, forms for a pre-funded warrant and two series of warrants, a legal opinion and consent from Blank Rome LLP, and two press releases described as a launch release and a pricing release. The filing also includes the interactive cover page data file. The disclosure signals a planned securities offering structure but does not include offering size, pricing terms, or proceeds in the attached exhibit list.

iBio, Inc. filed a prospectus supplement on Form 424B5 describing a securities offering that includes pre-funded warrants, Series G and Series H warrants, and related common stock issuances. The underwriters receive a commission equal to 6.0% of aggregate gross proceeds. The filing lists outstanding and reserved equity instruments as of March 31, 2025 and August 11, 2025, including stock options (weighted-average exercise prices $5.15 and $5.92), pre-funded warrants with a $0.0001 exercise price, previously issued warrants with weighted-average exercise prices of $2.30 and $1.30, and shares reserved under the 2023 Omnibus Equity Incentive Plan. The document discusses use of proceeds, risk factors, plan of distribution, restrictions on transfers and lock-up provisions, U.S. and non-U.S. holder tax rules, and where SEC filings are incorporated by reference. The prospectus also describes iBio’s AI-driven epitope engine, capital-efficient strategy emphasizing partnerships, tech licensing, and in-house preclinical programs focused on oncology, obesity and cardiometabolic diseases.